YOSO

YOSO Biosciences is an early-stage biotechnology company focused on developing a novel class of multi-specific antibody therapeutics. The company's proprietary YOSO platform utilizes a unique "Y-shaped" oligomer-based specificity optimizer to enhance the precision and efficacy of immune-oncology treatments. By engineering molecules that can simultaneously engage multiple targets with high affinity, YOSO aims to overcome the limitations of traditional monoclonal antibodies in treating complex solid tumors. The company is currently advancing a pipeline of pre-clinical candidates targeting well-validated pathways such as EGFR and HER2, while exploring synergistic combinations with checkpoint inhibitors.